<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Gene test interpretation: &lt;i&gt;MEFV &lt;/i&gt;(familial Mediterranean fever gene)</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Gene test interpretation: <i>MEFV </i>(familial Mediterranean fever gene)</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Gene test interpretation: <i>MEFV </i>(familial Mediterranean fever gene)</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eldad Ben-Chetrit, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anne Slavotinek, MBBS, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David S Pisetsky, MD, PhD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Shilpa Grover, MD, MPH, AGAF</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Siobhan M Case, MD, MHS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 16, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1559817660"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>This monograph summarizes the interpretation of germline testing of the<em> MEFV </em>gene, the gene associated with familial Mediterranean fever (FMF). </p><p>It does <strong>not</strong> discuss indications for testing and is not intended to replace clinical judgment in the decision to test or in the clinical care of the individual who was tested. These subjects are discussed separately [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H4081306597"><span class="h1">OVERVIEW</span></p><p class="headingAnchor" id="H394402957"><span class="h2">How to read the report</span><span class="headingEndMark"> — </span>An approach to reviewing a genetic test report is summarized in the checklist  (<a class="graphic graphic_table graphicRef122437" href="/d/graphic/122437.html" rel="external">table 1</a>).</p><p>Testing involves two steps: determining the genotype and interpreting the pathogenicity of the variant(s).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genotype</strong> – Identifies the variants in the gene(s) tested. Genotyping should be repeated in a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory if the results were obtained by direct-to-consumer testing or a research study and would impact clinical care (eg, positive finding, negative finding in an individual with a suspected diagnosis or syndrome). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Interpretation</strong> – Determines pathogenicity of the variants identified. (See <a class="local">'Classification of variants'</a> below.) </p><p></p><p>The table provides a glossary of genetic testing terms  (<a class="graphic graphic_table graphicRef122429" href="/d/graphic/122429.html" rel="external">table 2</a>).</p><p class="headingAnchor" id="H2434157243"><span class="h2">Classification of variants</span><span class="headingEndMark"> — </span>It is important to review which gene(s) were analyzed and which variants in those genes were tested, as some tests use comprehensive sequencing whereas others only screen for selected genes and/or selected variants. </p><p>The pathogenicity of each variant is classified by the testing laboratory into one of five categories based on information available at the time  (<a class="graphic graphic_table graphicRef122646" href="/d/graphic/122646.html" rel="external">table 3</a>) [<a href="#rid2">2</a>]. </p><p>The classification for many variants continues to be updated, especially for variants of uncertain significance (VUSs), as more evidence regarding pathogenicity (or lack thereof) becomes available. The uncertainty in the pathogenicity of variants reflects the current state of information available, rather than the accuracy of genotyping or the likelihood of disease.</p><p>If there is concern about the classification, such as for a VUS, obtain an updated interpretation periodically (eg, annually). Updating can be done by checking a database such as <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fclinvar%2F&amp;token=wEsKVFvqlKzpT%2BqOtddW%2Fy3%2BLj0shalBW%2BL1ZyL4trzGy12ipcVcj41059JRLkL3&amp;TOPIC_ID=140964" target="_blank">ClinVar</a>, contacting the laboratory, or consulting a clinical geneticist, genetic counselor, or other specialist (see <a class="local">'Locating a genetics expert'</a> below); there is no gold standard approach. Some laboratories routinely provide updates and others require a request. Likely benign and benign variants are not reported (or are reported as negative). Many VUSs are reclassified as benign.</p><p class="headingAnchor" id="H2945875672"><span class="h2">FMF genetics and disease associations</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>FMF</strong> – Familial Mediterranean fever (FMF) is a hereditary autoinflammatory disorder characterized by recurrent bouts of fever and serosal inflammation. Affected individuals can have recurrent attacks of fever and serositis (eg, peritonitis, pleuritis, pericarditis, synovitis) or erysipelas-like erythema. FMF has a variable expression, possibly due to other genetic and environmental factors. Progressive secondary (AA) amyloidosis is a devastating complication of FMF that may lead to renal failure and death. Recurrent attacks of peritonitis may lead to adhesions and small bowel obstruction.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>MEFV</em></strong><strong> gene</strong> – <em>MEFV</em> encodes pyrin, a protein expressed predominantly in myeloid lineage cells, synovial fibroblasts, and dendritic cells. Pyrin appears to act as a specific immune sensor (a pattern recognition receptor for bacterial toxins that modifies Rho GTPase interactions). Pathogenic variants in <em>MEFV</em> cause pyrin gain of function, which can lead to initiation and propagation of the inflammatory cascade even in the absence of provocation by a toxin or infection, resulting in an attack of FMF.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Common</strong><strong><em> MEFV</em></strong><strong> variants</strong> – Seventy-five percent of patients with "prototype FMF" (most of which are in the Middle East, Turkey, Israel, Iraq, Armenia, and Iran) carry pathogenic variants in exon 10 (apart from p.E148Q). These include p.M694V, p.M680I, p.M694I, and p.V726A. p.M694V is the most frequent in Middle Eastern populations, with a prevalence of 20 to 65 percent. However, in Japan, 75 percent of FMF patients carry pathogenic variants in exon 1 to 4 and the only pathogenic variant in exon 10 found in this population is p.M694I rather than p.M694V. Individuals who are homozygous for p.M694V variants tend to have more severe and earlier onset disease; as a result, these individuals may require higher <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">colchicine</a> doses to prevent attacks.</p><p></p><p class="bulletIndent1">Hundreds of other variants in <em>MEFV</em> have been identified. However, approximately 10 to 20 percent of individuals who meet diagnostic criteria for FMF have no identifiable variants in <em>MEFV</em>. (See  <a class="medical medical_review" href="/d/html/2634.html" rel="external">"Familial Mediterranean fever: Epidemiology, genetics, and pathogenesis", section on 'Genetics'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inheritance</strong> – In general, FMF is inherited as an autosomal recessive disease  (<a class="graphic graphic_figure graphicRef110582" href="/d/graphic/110582.html" rel="external">figure 1</a>). Biallelic pathogenic variants in <em>MEFV </em>must be present in the germline for the disease to manifest (homozygous or compound heterozygous). </p><p></p><p class="bulletIndent1">Individuals who are heterozygous for a pathogenic variant in <em>MEFV</em> are generally asymptomatic carriers, which explains why parents of an affected child may be unaffected and unaware that they carry the variant  (<a class="graphic graphic_figure graphicRef50124" href="/d/graphic/50124.html" rel="external">figure 2</a>). However, approximately 2 to 5 percent of heterozygous individuals may display FMF, and these individuals account for approximately 33 percent of FMF patients in endemic countries [<a href="#rid3">3,4</a>]. In addition, there are rare cases where FMF is transmitted as an autosomal dominant trait. This pattern of transmission happens with the following <em>MEFV</em> variants: p.M692del, p.H478Y, and p.T577N [<a href="#rid5">5-7</a>]. Additional genetic and environmental modifiers that influence the phenotypic expression of the disease are hypothesized to exist but are not well understood.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – In endemic countries, the diagnosis of FMF is made on the basis of clinical symptoms and can be supported by ancestry information and family history  (<a class="graphic graphic_algorithm graphicRef77816" href="/d/graphic/77816.html" rel="external">algorithm 1</a> and <a class="graphic graphic_table graphicRef67666" href="/d/graphic/67666.html" rel="external">table 4</a>). Genetic testing for FMF serves to support the diagnosis in patients who meet clinical criteria for FMF, to counsel at-risk relatives, and to guide the therapeutic approach [<a href="#rid8">8</a>]. While ancestry information may affect the determination of disease prevalence, lack of common ancestries cannot be used to exclude the diagnosis of FMF. In countries where FMF is rare, genetic testing has a significant role in diagnosis. (See  <a class="medical medical_review" href="/d/html/2635.html" rel="external">"Clinical manifestations and diagnosis of familial Mediterranean fever", section on 'Diagnosis'</a>.)</p><p></p><p class="bulletIndent1">In individuals who meet clinical criteria for FMF but in whom genetic testing is not diagnostic (heterozygosity for a pathogenic variant in <em>MEFV</em> or negative genetic testing), the diagnosis of FMF is supported by a six-month trial of <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">colchicine</a> therapy that results in a relief of attacks and recurrence after cessation of treatment [<a href="#rid3">3</a>]. However, a <strong>definitive diagnosis</strong> of FMF requires genetic confirmation. </p><p></p><p class="headingAnchor" id="H3691853875"><span class="h1">IMPLICATIONS OF A BIALLELIC PATHOGENIC OR LIKELY PATHOGENIC VARIANT</span><span class="headingEndMark"> — </span>For purposes of counseling, we treat all biallelic (homozygous or compound heterozygous) germline variants in <em>MEFV</em> that are pathogenic or likely pathogenic the same, regardless of the initial reason for testing and the family history  (<a class="graphic graphic_algorithm graphicRef143261" href="/d/graphic/143261.html" rel="external">algorithm 2</a>). </p><p>Discussion should include:</p><p class="bulletIndent1"><span class="glyph">●</span>Typical symptoms of an attack and how to seek help.</p><p class="bulletIndent1"><span class="glyph">●</span>Long-term complications and preventive strategies.</p><p class="bulletIndent1"><span class="glyph">●</span>Treatment with <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">colchicine</a>, including dosing, adverse effects, and expected response.</p><p class="bulletIndent1"><span class="glyph">●</span>Options for individuals who cannot tolerate colchicine or whose disease does not respond to colchicine.</p><p class="bulletIndent1"><span class="glyph">●</span>Pregnancy and nursing-specific considerations.</p><p></p><p>Counseling may require additional visits or referral to a genetic counselor or clinical geneticist. </p><p>Additional details and supporting evidence are discussed separately. (See  <a class="medical medical_review" href="/d/html/2635.html" rel="external">"Clinical manifestations and diagnosis of familial Mediterranean fever"</a> and  <a class="medical medical_review" href="/d/html/2574.html" rel="external">"Management of familial Mediterranean fever"</a>.)</p><p class="headingAnchor" id="H1228186276"><span class="h1">HETEROZYGOUS INDIVIDUALS</span><span class="headingEndMark"> — </span>Approximately 95 to 98 percent of heterozygous individuals are asymptomatic carriers and do not have FMF. However, the remaining 2 to 5 percent of heterozygous individuals meet diagnostic criteria for FMF; these individuals are thought to have other factors that contribute to disease manifestations. (See <a class="local">'FMF genetics and disease associations'</a> above.)</p><p>Heterozygous individuals who meet diagnostic criteria for FMF  (<a class="graphic graphic_table graphicRef67666" href="/d/graphic/67666.html" rel="external">table 4</a>) are treated with <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">colchicine</a> similar to those with biallelic pathogenic variants. For rare cases of heterozygous FMF patients who are asymptomatic for several (more than five) years and do not display elevated acute phase reactants, it may be possible to discontinue colchicine. (See  <a class="medical medical_review" href="/d/html/2574.html" rel="external">"Management of familial Mediterranean fever", section on 'Colchicine'</a>.)</p><p>Those who do not meet diagnostic criteria can be counseled that they do not have FMF. However, individuals carrying a single variant may develop FMF late in life  (<a class="graphic graphic_algorithm graphicRef143261" href="/d/graphic/143261.html" rel="external">algorithm 2</a>). (See <a class="local">'Considerations for relatives'</a> below.)</p><p class="headingAnchor" id="H2985650496"><span class="h1">IMPLICATIONS OF A NEGATIVE TEST</span><span class="headingEndMark"> — </span>Negative testing means that no pathogenic or likely pathogenic variants were identified. However, some tests only query a subset of variants; pathogenic variants might be present in other parts of the gene (if testing was not comprehensive).</p><p>Approximately 10 to 20 percent of patients who meet clinical diagnostic criteria for FMF do not carry any pathogenic variants in <em>MEFV</em> [<a href="#rid9">9,10</a>]. In these cases, the diagnosis of FMF is considered probable rather than definitive. Thus, the following considerations apply:</p><p class="bulletIndent1"><span class="glyph">●</span>A negative test cannot be used to exclude FMF in an individual with clinical features of the disease. Additional testing may be indicated, such as more extensive testing of <em>MEFV</em> or testing of other genes  (<a class="graphic graphic_algorithm graphicRef143261" href="/d/graphic/143261.html" rel="external">algorithm 2</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For individuals with a positive family history in which the familial <em>MEFV</em> variants are known and the tested individual does not carry those variants, usually they can be reassured that they are not at high risk for FMF. However, it is important to assess family history to provide an individualized risk assessment. (See <a class="local">'Locating a genetics expert'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For individuals with a positive family history in which the familial <em>MEFV</em> variant(s) are not known, the affected individuals should undergo genetic testing first (before unaffected individuals). Referral to a clinical geneticist or genetic counselor may be helpful in determining the optimal testing strategy in those with a family history suggestive of FMF. (See <a class="local">'Locating a genetics expert'</a> below.)</p><p></p><p class="headingAnchor" id="H2814822250"><span class="h1">IMPLICATIONS OF A VARIANT OF UNKNOWN SIGNIFICANCE</span><span class="headingEndMark"> — </span>Individuals with a variant of uncertain significance (VUS) should be managed based on their personal and family history, their clinical manifestations, and not the VUS  (<a class="graphic graphic_algorithm graphicRef143261" href="/d/graphic/143261.html" rel="external">algorithm 2</a>).</p><p>New information may become available, and the testing laboratory or other resources should be consulted periodically for updates in the classification (eg, annually).</p><p class="headingAnchor" id="H2837022539"><span class="h1">CONSIDERATIONS FOR RELATIVES</span></p><p class="headingAnchor" id="H1007017044"><span class="h2">Reproductive counseling</span><span class="headingEndMark"> — </span>FMF is generally an autosomal recessive disease.</p><p class="bulletIndent1"><span class="glyph">●</span>Children of an affected individual who has biallelic pathogenic variants in <em>MEFV </em>will be obligate carriers of one or the other variant. The children of such an individual could be affected with FMF if their other parent is also a carrier of a disease variant; as a result, such a child may inherit a pathogenic variant in <em>MEFV</em> from both parents. Nevertheless, some children may display FMF even with a single pathogenic variant they inherited from their parent who has biallelic variants.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Siblings of an individual with FMF whose parents are both unaffected carriers have a 25 percent chance of inheriting a pathogenic variant from both parents and being affected. They have a 50 percent chance of being heterozygous and unaffected and a 25<em> </em>percent chance of not inheriting either of the pathogenic variants in <em>MEFV</em>. (See <a class="local">'Heterozygous individuals'</a> above and <a class="local">'Implications of a biallelic pathogenic or likely pathogenic variant'</a> above.) </p><p></p><p class="headingAnchor" id="H121586399"><span class="h2">At-risk relatives</span><span class="headingEndMark"> — </span>Individuals who test positive for a pathogenic variant or likely pathogenic variant should inform their at-risk relatives about the importance of genetic counseling and possible testing if they have elevated acute phase reactants that are suggestive of subclinical inflammation.</p><p>Full siblings of an individual with biallelic germline <em>MEFV</em> variants have a 25 percent chance of having inherited both <em>MEFV</em> variants and a 50 percent chance of being heterozygous carriers of a single <em>MEFV</em> variant. (See <a class="local">'Heterozygous individuals'</a> above.)</p><p class="headingAnchor" id="H77494736"><span class="h1">RESOURCES</span></p><p class="headingAnchor" id="H984902151"><span class="h2">UpToDate topics</span></p><p class="bulletIndent1"><span class="glyph">●</span>FMF:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Clinical manifestations, diagnosis, and management – (See  <a class="medical medical_review" href="/d/html/2634.html" rel="external">"Familial Mediterranean fever: Epidemiology, genetics, and pathogenesis"</a> and  <a class="medical medical_review" href="/d/html/2635.html" rel="external">"Clinical manifestations and diagnosis of familial Mediterranean fever"</a> and  <a class="medical medical_review" href="/d/html/2574.html" rel="external">"Management of familial Mediterranean fever"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Genetics:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Variant classification – (See  <a class="medical medical_review" href="/d/html/2900.html" rel="external">"Basic genetics concepts: DNA regulation and gene expression", section on 'Clinical classification of pathogenicity'</a>.) </p><p class="bulletIndent2"><span class="glyph">•</span>Terminology – (See  <a class="medical medical_review" href="/d/html/2898.html" rel="external">"Genetics: Glossary of terms"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>Genetic testing – (See  <a class="medical medical_review" href="/d/html/2901.html" rel="external">"Genetic testing"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>Genetic counseling – (See  <a class="medical medical_review" href="/d/html/103304.html" rel="external">"Genetic counseling: Family history interpretation and risk assessment"</a>.)</p><p></p><p class="headingAnchor" id="H1368175390"><span class="h2">Locating a genetics expert</span></p><p class="bulletIndent2"><span class="glyph">•</span>Clinical geneticists – American College of Medical Genetics and Genomics (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinics.acmg.net%2F&amp;token=nbsXe3i4qfUea5RCPRHtOdEP95SDL7NSm8b1jbZpdwjlW9H1hfmmq%2FTbAbE64qhV&amp;TOPIC_ID=140964" target="_blank">ACMG</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Genetic counselors – National Society of Genetic Counselors (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Ffindageneticcounselor.nsgc.org%2F&amp;token=AU2cQkyAZolWVu502Wzur%2F2gjdsB%2FYlqRYYyoKtNflwwaDFffULns7AVKZBF0Vtm&amp;TOPIC_ID=140964" target="_blank">NSGC</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>National Institutes of Health (NIH) Cancer Genetics <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cancer.gov%2Fabout-cancer%2Fcauses-prevention%2Fgenetics%2Fdirectory&amp;token=j%2Fp%2BIZfImoJgnd%2Fk4T5MAbDlZmLADFk1VrVOJqDdPzf1mGWFw3YadpFlBYSMxNKDeExYMR0QNQoNISFKbh7RPtm%2BfHLonSi2ZDCqhRzTq0w%3D&amp;TOPIC_ID=140964" target="_blank">Services Directory</a> </p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Supporting references are provided in the associated UpToDate topics, with selected citation(s) below.</li><li><a class="nounderline abstract_t">Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015; 17:405.</a></li><li><a class="nounderline abstract_t">Booty MG, Chae JJ, Masters SL, et al. Familial Mediterranean fever with a single MEFV mutation: where is the second hit? Arthritis Rheum 2009; 60:1851.</a></li><li><a class="nounderline abstract_t">Samuels J, Aksentijevich I, Torosyan Y, et al. Familial Mediterranean fever at the millennium. Clinical spectrum, ancient mutations, and a survey of 100 American referrals to the National Institutes of Health. Medicine (Baltimore) 1998; 77:268.</a></li><li><a class="nounderline abstract_t">Aldea A, Campistol JM, Arostegui JI, et al. A severe autosomal-dominant periodic inflammatory disorder with renal AA amyloidosis and colchicine resistance associated to the MEFV H478Y variant in a Spanish kindred: an unusual familial Mediterranean fever phenotype or another MEFV-associated periodic inflammatory disorder? Am J Med Genet A 2004; 124A:67.</a></li><li><a class="nounderline abstract_t">Stoffels M, Szperl A, Simon A, et al. MEFV mutations affecting pyrin amino acid 577 cause autosomal dominant autoinflammatory disease. Ann Rheum Dis 2014; 73:455.</a></li><li><a class="nounderline abstract_t">Nakaseko H, Iwata N, Izawa K, et al. Expanding clinical spectrum of autosomal dominant pyrin-associated autoinflammatory disorder caused by the heterozygous MEFV p.Thr577Asn variant. Rheumatology (Oxford) 2019; 58:182.</a></li><li><a class="nounderline abstract_t">Babior BM, Matzner Y. The familial Mediterranean fever gene--cloned at last. N Engl J Med 1997; 337:1548.</a></li><li><a class="nounderline abstract_t">Padeh S, Shinar Y, Pras E, et al. Clinical and diagnostic value of genetic testing in 216 Israeli children with Familial Mediterranean fever. J Rheumatol 2003; 30:185.</a></li><li><a class="nounderline abstract_t">Ben-Zvi I, Herskovizh C, Kukuy O, et al. Familial Mediterranean fever without MEFV mutations: a case-control study. Orphanet J Rare Dis 2015; 10:34.</a></li></ol></div><div id="topicVersionRevision">Topic 140964 Version 5.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Supporting references are provided in the associated UpToDate topics, with selected citation(s) below.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25741868" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19479870" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Familial Mediterranean fever with a single MEFV mutation: where is the second hit?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9715731" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Familial Mediterranean fever at the millennium. Clinical spectrum, ancient mutations, and a survey of 100 American referrals to the National Institutes of Health.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14679589" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : A severe autosomal-dominant periodic inflammatory disorder with renal AA amyloidosis and colchicine resistance associated to the MEFV H478Y variant in a Spanish kindred: an unusual familial Mediterranean fever phenotype or another MEFV-associated periodic inflammatory disorder?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23505238" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : MEFV mutations affecting pyrin amino acid 577 cause autosomal dominant autoinflammatory disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30203097" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Expanding clinical spectrum of autosomal dominant pyrin-associated autoinflammatory disorder caused by the heterozygous MEFV p.Thr577Asn variant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9366590" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The familial Mediterranean fever gene--cloned at last.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12508410" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Clinical and diagnostic value of genetic testing in 216 Israeli children with Familial Mediterranean fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25887307" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Familial Mediterranean fever without MEFV mutations: a case-control study.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
